- Home
- IDR vs IKT Comparison
IDR vs IKT Comparison
Compare IDR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- IKT
- Stock Information
- Founded
- IDR 1996
- IKT 2008
- Country
- IDR United States
- IKT United States
- Employees
- IDR N/A
- IKT N/A
- Industry
- IDR Precious Metals
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- IKT Health Care
- Exchange
- IDR Nasdaq
- IKT Nasdaq
- Market Cap
- IDR 154.1M
- IKT 167.2M
- IPO Year
- IDR N/A
- IKT 2020
- Fundamental
- Price
- IDR $18.08
- IKT $1.90
- Analyst Decision
- IDR Strong Buy
- IKT Buy
- Analyst Count
- IDR 1
- IKT 2
- Target Price
- IDR $17.50
- IKT $8.00
- AVG Volume (30 Days)
- IDR 334.9K
- IKT 147.0K
- Earning Date
- IDR 05-05-2025
- IKT 05-14-2025
- Dividend Yield
- IDR N/A
- IKT N/A
- EPS Growth
- IDR 644.44
- IKT N/A
- EPS
- IDR 0.67
- IKT N/A
- Revenue
- IDR $25,765,373.00
- IKT N/A
- Revenue This Year
- IDR $9.76
- IKT N/A
- Revenue Next Year
- IDR N/A
- IKT N/A
- P/E Ratio
- IDR $26.99
- IKT N/A
- Revenue Growth
- IDR 88.66
- IKT N/A
- 52 Week Low
- IDR $7.59
- IKT $1.12
- 52 Week High
- IDR $18.35
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- IDR 68.96
- IKT 42.84
- Support Level
- IDR $14.06
- IKT $1.58
- Resistance Level
- IDR $18.33
- IKT $2.22
- Average True Range (ATR)
- IDR 1.45
- IKT 0.22
- MACD
- IDR 0.32
- IKT 0.00
- Stochastic Oscillator
- IDR 75.19
- IKT 45.57
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.